Literature DB >> 23685907

Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more.

Mark Ng Tang Fui1, Mathis Grossmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23685907      PMCID： PMC3739248          DOI： 10.1038/aja.2013.57

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  8 in total

1.  Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

Authors:  Mathis Grossmann; Jeffrey D Zajac
Journal:  Clin Endocrinol (Oxf)       Date:  2011-03       Impact factor: 3.478

Review 2.  Management of side effects of androgen deprivation therapy.

Authors:  Mathis Grossmann; Jeffrey D Zajac
Journal:  Endocrinol Metab Clin North Am       Date:  2011-09       Impact factor: 4.741

3.  Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.

Authors:  A S Cheung; D Pattison; I Bretherton; R Hoermann; D Lim Joon; E Ho; T Jenkins; E J Hamilton; K Bate; I Chan; J D Zajac; M Grossmann
Journal:  Andrology       Date:  2013-05-20       Impact factor: 3.842

4.  Intermittent androgen suppression for rising PSA level after radiotherapy.

Authors:  Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

Review 5.  Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Authors:  Mathis Grossmann; Emma J Hamilton; Christopher Gilfillan; Damien Bolton; Daryl Lim Joon; Jeffrey D Zajac
Journal:  Med J Aust       Date:  2011-03-21       Impact factor: 7.738

Review 6.  Hematological changes during androgen deprivation therapy.

Authors:  Mathis Grossmann; Jeffrey D Zajac
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

7.  Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.

Authors:  K Akakura; N Bruchovsky; S L Goldenberg; P S Rennie; A R Buckley; L D Sullivan
Journal:  Cancer       Date:  1993-05-01       Impact factor: 6.860

8.  Intermittent versus continuous androgen deprivation in prostate cancer.

Authors:  Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.